Jelly Lean gummy supplement rides viral "Pink Gelatin Trick" wave
A dietary supplement brand called Jelly Lean has emerged as one of the more searched weight-management products in the first half of 2026, propelled by the spread of the so-called "Pink Gelatin Trick" — a social media trend centred on consuming a gelatin-based preparation before meals to support satiety and reduce snacking.
The company behind the product, trading as JellyLean Research and distributing via ClickBank, says demand has grown rapidly enough to attract a wave of copycat and counterfeit listings on major online marketplaces. The source release for this brief is a promotional "investigation" carrying affiliate-link dislosures and is distributed via GlobeNewswire by the brand itself. It does not constitute independent journalism. Readers should treat the ingredient efficacy claims below as company-sourced and not validated by a third party.
What is the product?
Jelly Lean is a once-daily chewable gummy containing a 525 mg proprietary blend of apple cider vinegar (ACV) and exogenous BHB salts — Calcium BHB, Magnesium BHB, and Sodium BHB — alongside trace amounts of calcium, magnesium, and sodium as electrolyte carriers. The official single-bottle price is listed at $69 for a 30-day supply. The company says the product is assembled in a US-based GMP-compliant facility and sold exclusively through its own website, jellylean.com.
The brand positions the gummy as a "multi-pathway metabolic support" formula rather than a pharmaceutical intervention. ACV is cited for its acetic acid content, which some peer-reviewed studies have linked to delayed gastric emptying and modest reductions in post-meal blood glucose. BHB salts are presented as exogenous ketones that may transiently elevate blood ketone concentrations and, separately, suppress ghrelin — the primary hunger-signalling hormone. The company acknowledges that no clinical trials have been conducted on the finished Jelly Lean formulation itself; the scientific rationale rests on ingredient-level research only.
Market context and regulatory landscape
The ACV gummy category has expanded considerably since 2021, with dozens of brands occupying the same ingredient territory. The category sits in an ambiguous regulatory position: dietary supplements in the United States do not require pre-market approval from the FDA, and manufacturers are not obliged to demonstrate efficacy before listing a product for sale. The FDA's authority is largely reactive, acting on consumer complaints or adverse event reports after a product reaches the market.
The broader cultural backdrop is also relevant. Consumer interest in GLP-1 receptor agonists — drugs such as semaglutide — has materially raised public awareness of appetite-regulating biology. That awareness appears to be creating downstream demand for non-prescription alternatives that claim to operate on similar metabolic pathways through "natural" ingredients. ACV-and-ketone gummies are a direct beneficiary of that shift in consumer framing, even though the clinical evidence base for such supplements is considerably thinner than for approved GLP-1 therapies.
The counterfeit problem the brand describes is not unusual in the supplement sector. Third-party marketplace listings using a brand's name while selling an entirely different formulation represent a known enforcement gap. The brand claims to have identified at least three distinct products — sold under the names OVICIA (Amazon), Fyvus (Walmart), and Sigma Times (eBay) — operating under the Jelly Lean name with different ingredient profiles and price points as low as $19.95.
The forward-looking question for the category is whether intensifying regulatory scrutiny of the supplement marketplace — the FTC has signalled increased attention to influencer-driven health product marketing — will constrain the viral distribution model on which brands like Jelly Lean depend. For now, the company is riding the trend; sustaining that position will require either clinical substantiation or continued social-media momentum.